Ann Lab Med.  2018 Sep;38(5):446-449. 10.3343/alm.2018.38.5.446.

Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients

• Karakecili F
• Cikman A
• Aydin M
• Gulhan B

• KMID: 2434734
• DOI: http://doi.org/10.3343/alm.2018.38.5.446

Abstract

BACKGROUND
High asymmetrical dimethylarginine (ADMA) levels have been associated with endothelial dysfunction and contribute to the development of several diseases. However, data on the relationship between hepatitis B virus (HBV) and ADMA are limited. The aim of our study was to explore the relationship between ADMA and HBV by comparing the ADMA levels in patients with chronic active hepatitis B (CHB), inactive HBV carriers (carriers), and healthy volunteers (controls).
METHODS
The participants were divided into three groups: 90 patients with CHB, 90 HBV carriers, and 90 controls. Serum ADMA levels were quantified using an ELISA kit (Cusabio, Wuhan, China). The data were analyzed using an ANOVA or the Kruskal-Wallis test as appropriate, with P<0.05 considered significant.
RESULTS
Serum ADMA levels were significantly higher in patients with CHB (228.35±91.10 ng/mL) than in HBV carriers (207.80±75.80 ng/mL) and controls (207.61±89.10 ng/mL) (P=0.049). The clinical scores of the patients were positively correlated with ADMA levels.
CONCLUSIONS
The elevated serum ADMA levels in patients with CHB confirm that HBV plays a role in vasculitis. Further investigation of the mechanisms contributing to the high levels of ADMA in CHB may contribute toward development of new treatment modalities.

Keyword

Asymmetric dimethylarginine; Hepatitis B virus; Chronic active hepatitis B; Inactive hepatitis B virus carrier

MeSH Terms

Enzyme-Linked Immunosorbent Assay
Healthy Volunteers
Hepatitis B virus
Hepatitis B*
Hepatitis*
Hepatitis, Chronic
Humans
Vasculitis

Reference

1. Aldámiz-Echevarría L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci. 2012; 13:11288–11311. PMID: 23109853.

2. Liu X, Hou L, Xu D, Chen A, Yang L, Zhuang Y, et al. Effect of asymmetric dimethlarginine (ADMA) on heart failure development. Nitric Oxide. 2016; 54:73–81. PMID: 26923818.

3. Tain YL, Hsu CN. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel). 2017; 9:E92. DOI: 10.3390/toxins9030092. PMID: 28272322.

4. McCarty MF. Asymmetric dimethylarginine is a well-established mediating risk factor for cardiovascular morbidity and mortality-should patients with elevated levels be supplemented with citrulline? Healthcare (Basel). 2016; 4:E40. DOI: 10.3390/healthcare4030040. PMID: 27417628.

5. Erbil MK, Kurt YG, Yaman H, Çaır E, Akgül EÖ, Çaycı T. Metabolism of asymmetric dimethylarginine and its clinical significance. Turk J Bioch. 2012; 37:99–105.

6. El Dayem SM, Battah AA, El-Shehaby A, El Bohy AE. Asymmetric dimethyl L-arginine, nitric oxide and cardiovacular disease in adolescent type 1 diabetics. J Pediatr Endocrinol Metab. 2014; 27:437–444. PMID: 24468606.

7. Taşkıran B, Uğur Altun B, Vardar SA, Demir AM, Karadağ ÇH, Altun A. Effect of exercise on ADMA level in type 2 diabetes mellitus. Balkan Med J. 2012; 29:62–67.

8. Sitar ME. Asymmetric dimethylarginine and its relation as a biomarker in nephrologic diseases. Biomark Insights. 2016; 11:131–137. PMID: 27980388.

9. Ittermann T, Bahls M, Atzler D, Friedrich N, Schwedhelm E, Böger RH, et al. L-Arginine derivatives are associated with the hyperthyroid state in the general population. Thyroid. 2016; 26:212–218. PMID: 26650143.

10. Aydemir O, Ozcan B, Yucel H, Bas AY, Demirel N. Asymmetric dimethylarginine and L-arginine levels in neonatal sepsis and septic shock. J Matern Fetal Neonatal Med. 2015; 28:977–982. PMID: 24983667.

11. Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World J Gastroenterol. 2015; 21:5131–5137. PMID: 25954086.

12. Mengeloglu Z, Sünnetcioglu M, Tosun M, Kücükbayrak A, Ceylan MR, Baran AI, et al. High asymmetric dimethylarginine (ADMA) levels in patients with brucellosis. Inflammation. 2014; 37:127–131. PMID: 23978912.

13. Baranyi A, Meinitzer A, Putz-Bankuti C, Stauber R, Kapfhammer HP, Rothenhäusler HB. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med. 2014; 76:197–207. PMID: 24608038.

14. Hu J, Liu K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses. 2017; 9:E56. PMID: 28335554.

15. Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B virus immunopathology, model systems, and current therapies. Front Immunol. 2017; 8:436. PMID: 28450868.

16. An J, Lim YS, Kim GA, Han SB, Jeong W, Lee D, et al. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. BMC Gastroenterol. 2017; 17:15. PMID: 28103819.

17. Joshi U, Subedi R, Gajurel BP. Hepatitis B virus induced cytoplasmic antineutrophil cytoplasmic antibody-mediated vasculitis causing subarachnoid hemorrhage acute transverse myelitis, and nephropathy: a case report. J Med Case Rep. 2017; 11:91. PMID: 28366165.

18. Ishak K, Baptista A, Bianch L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22:696–699. PMID: 7560864.

19. Lluch P, Segarra G, Medina P. Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis. World J Gastroenterol. 2015; 21:9466–9475. PMID: 26327755.

20. Nicković V, Nikolić J, Djindjić N, Ilić M, Nicković J, Mladenović D, et al. Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis. Vojnosanit Pregl. 2012; 69:686–691. PMID: 22924265.

21. Brenner T, Flemin TH, Rosenhagen C, Krauser U, Mieth M, Bruckner T, et al. L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediators Inflamm. 2012; 2012:210454. PMID: 22619480.

22. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in several alcoholic hepatitis. Hepatology. 2007; 45:62–71. PMID: 17187433.

23. Beltrán LM, Hernández RM, de Pablo Bernal RS, Morillo JSG, Egido J, Noval ML, et al. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 2014; 9:e90541. PMID: 24594990.

24. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5:e203. PMID: 18942885.

25. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dsyfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 2009; 10:79–87. PMID: 19200170.

26. Lluch P, Cortina B, Vila JM, Segarra G, Mauricio MD, Del Olmo JA, et al. Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C. Scand J Gastroenterol. 2009; 44:224–228. PMID: 18951278.